Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 35 - Antineoplastic agents
Patents for A61P 35 - Antineoplastic agents (221,099)
12/2010
12/07/2010US7846446 Polypeptide comprising matriptase domain for use in treatment and prevention of ovarian cell proliferative disorders
12/07/2010US7846441 Treatment with anti-ErbB2 antibodies
12/07/2010US7846440 Antibodies against ErbB3 and uses thereof
12/07/2010US7846429 Compositions and methods for elimination of unwanted cells
12/07/2010CA2488334C 24-sulfoximine vitamin d3 compounds
12/07/2010CA2460693C Alkyl urea retinoid agonists i
12/07/2010CA2456029C Stable emulsion composition
12/07/2010CA2440111C Combinations comprising an antidiarrheal agent and an epothilone or an epothilone derivative
12/07/2010CA2434203C 2-arylimino-2,3-dihydrothiazole derivatives, methods for preparing them and therapeutic use thereof
12/07/2010CA2417570C Tumor-specific t cell activation by peptide antigens
12/07/2010CA2398335C Herpes virus strains
12/07/2010CA2383224C Extracts of orange peel for prevention and treatment of cancer
12/07/2010CA2352094C High energy phototherapeutic agents
12/07/2010CA2299632C Substituted quinazoline derivatives and their use as tyrosine kinase inhibitors
12/07/2010CA2256543C Methods and compositions useful for inhibition of angiogenesis
12/07/2010CA2153653C Growth differentiation factor-9
12/02/2010WO2010138955A2 Methods and compositions for treating neoplasia
12/02/2010WO2010138839A2 Use of 2 anti-sparc antibodies to predict response to chemotherapy
12/02/2010WO2010138803A2 Herv-k antigens, antibodies, and methods
12/02/2010WO2010138725A1 Treatment of pancreatic cancer using a dr5 agonist in combination with gemcitabine
12/02/2010WO2010138673A1 Inhibitors of c-met protein kinase
12/02/2010WO2010138665A1 Aminopyrazole triazolothiadiazole inhibitors of c-met protien kinase
12/02/2010WO2010138663A1 Substituted pyrazole inhibitors of c-met protein kinase
12/02/2010WO2010138589A1 Bicyclic pyrimidine pi3k inhibitor compounds selective for p110 delta, and methods of use
12/02/2010WO2010138576A1 Pyrimidine inhibitors of kinase activity
12/02/2010WO2010138575A1 Pyrimidine inhibitors of kinase activity
12/02/2010WO2010138490A1 Benzoxazepines as inhibitors of mtor and methods of their use and manufacture
12/02/2010WO2010138487A1 BENZOXAZEPINES AS INHIBITORS OF PI3K/m TOR AND METHODS OF THEIR USE AND MANUFACTURE
12/02/2010WO2010138171A2 Methods for cancer treatment using stem cells
12/02/2010WO2010138101A1 Combination therapy for the treatment of multiple myeloma using cep-18770 together with bortezomib or mephalan
12/02/2010WO2010137944A1 Treatment of hypercalcaemia
12/02/2010WO2010137939A1 Method for producing a nutraceutical composition and the nutraceutical produced by the method
12/02/2010WO2010137654A1 Pharmaceutical composition containing antagonist of egf family ligand as component
12/02/2010WO2010137620A1 Phenoxyethylamine derivative
12/02/2010WO2010137570A1 Anti-viral agent or an anti-cancer agent
12/02/2010WO2010137351A1 Aryl substituted carboxamide derivatives as calcium or sodium channel blockers
12/02/2010WO2010137295A1 Cdc45l peptides and vaccines including the same
12/02/2010WO2010137012A1 Peptide therapy for amphiregulin mediated diseases
12/02/2010WO2010136846A1 Differentiation therapy for sarcomas
12/02/2010WO2010136778A1 Dibenzothiophene derivatives as dna- pk inhibitors
12/02/2010WO2010136755A1 Substituted benzotriazines and quinoxalines as inhibitors of p7os6 kinase
12/02/2010WO2010136705A1 Pharmaceutical antitumor composition including a cdk inhibitor and a cell-growth inhibitor
12/02/2010WO2010136559A1 2, 4 -diaminopyrimidines for the treatment of diseases characterised by excessive or abnormal cell proliferation
12/02/2010WO2010136536A1 Anti-ck8 antibodies to be used for treating colorectal cancers and identifying metastatic and/or invasive phenotypes
12/02/2010WO2010136482A1 Antigen-binding proteins
12/02/2010WO2010136449A1 Akg composition and use thereof in the production of a drug
12/02/2010WO2010136443A1 Casb7439 constructs
12/02/2010WO2010136137A1 Substituted piperidines
12/02/2010WO2010136127A1 Substituted 3-(1,2,4-oxadiazol-5-yl)-5-phenylpiperidines
12/02/2010WO2010135908A1 N-(2-amino-4-pyridyl) benzamide derivatives and uses thereof
12/02/2010WO2010111254A9 NOVEL ANTI-α5β1 ANTIBODIES AND USES THEREOF
12/02/2010WO2010108251A3 Antineoplastic testosterone molecular complex
12/02/2010WO2010103547A3 Substituted fused pyrimidine compounds
12/02/2010WO2010093789A3 A composition comprising (-) -trans-3- (5, 6-dihydro-4h-pyrrolo [3,2,1-ij] quinolin-l-yl)-4-(lh-indol-3-yl) pyrrolidine- 2, 5-dione in combination with a second anti-proliferative agent
12/02/2010WO2010091192A3 Nanoscale platinum compounds and methods of use thereof
12/02/2010WO2010085588A3 Modulating angiogenesis
12/02/2010WO2010083385A3 Compounds for reducing drug resistance and uses thereof
12/02/2010WO2010080124A9 Nkg2d-fc for immunotherapy
12/02/2010WO2010078945A3 Cancer treatment
12/02/2010WO2010068923A3 Agents that selectively inhibit cd25 on dendritic cells or t cells and their use
12/02/2010WO2010059253A3 Methods and compositions for localized agent delivery
12/02/2010WO2010057028A3 Treatment of proteinopathies using a farnesyl transferase inhibitor
12/02/2010WO2010049438A3 Improved methods of using phosphoantigens for the treatment of diseases
12/02/2010WO2009133545A3 Vascular delivery systems
12/02/2010WO2009067243A8 Modulation of cd40 expression
12/02/2010US20100305500 Hyaluronidase as an adjuvant for increasing the injection volume and dispersion of large diameter synthetic membrane vesicles containing a therapeutic agent
12/02/2010US20100305202 Lyophilized pharmaceutical composition with improved stability containing taxane derivatives, and method of manufacturing the same
12/02/2010US20100305201 Method of Treating a Tumor and Biodistribution of a Drug Delivered by Worm-Like Filomicelles
12/02/2010US20100305199 Therapeutic regimen for treating cancer
12/02/2010US20100305197 Conditionally Active Ribozymes And Uses Thereof
12/02/2010US20100305196 COMPOSITION FOR TREATING PROSTATE CANCER (PCa)
12/02/2010US20100305191 Rna interference mediated inhibition of adenosine a1 receptor (adora1) gene expression using short interfering rna
12/02/2010US20100305188 Nucleic acid capable of regulating the proliferation of cell
12/02/2010US20100305186 Methods for mediating gene suppression
12/02/2010US20100305184 Inhibitors of the atb(0,+) transporter and uses thereof
12/02/2010US20100305180 Inhibitors of ubiquitin e1
12/02/2010US20100305176 (s,r.)-3-phenyl-4,5 dihydro-5-isoxazole acetic acid-nitric oxide and use thereof as anti-cancer and antiviral agent
12/02/2010US20100305174 Novel Heterocyclic Derivatives
12/02/2010US20100305167 Administration of an Inhibitor of HDAC
12/02/2010US20100305156 Inhibitors of c-met protein kinase
12/02/2010US20100305155 Substituted pyrazole inhibitors of c-met protein kinase
12/02/2010US20100305151 O-Methylated Rapamycin Derivatives For Alleviation And Inhibition Of Lymphoproliferative Disorders
12/02/2010US20100305149 Polyal Drug Conjugates Comprising Variable Rate-Releasing Linkers
12/02/2010US20100305148 Di-ester prodrugs of camptothecin, process for their preparation and their therapeutical applications
12/02/2010US20100305147 Chemically modified small molecules
12/02/2010US20100305143 Pyrrolopyrimidine compounds
12/02/2010US20100305136 Quinolone analogs derivatized with sulfonic acid, sulfonate or sulfonamide
12/02/2010US20100305131 Substituted Aminopropionic Derivatives as Neprilysin inhibitors
12/02/2010US20100305129 Compositions and methods for inhibiting growth and metastasis of melanoma
12/02/2010US20100305128 Pyrimidinyl-Thiophene Kinase Modulators
12/02/2010US20100305126 Pyrimidine Inhibitors of Kinase Activity
12/02/2010US20100305125 Salt of abt-263 and solid-state forms thereof
12/02/2010US20100305123 Class of histone deacetylase inhibitors
12/02/2010US20100305122 Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseases
12/02/2010US20100305121 Novel antagonists of the human fatty acid synthase thioesterase
12/02/2010US20100305118 Pyrimidine inhibitors of kinase activity
12/02/2010US20100305113 Substituted Imidazopyridazines as Lipid Kinase Inhibitors
12/02/2010US20100305112 Pyrimidine inhibitors of kinase activity
12/02/2010US20100305106 Inhibitors of fatty acid uptake and methods of use
12/02/2010US20100305104 Oxadiazole Diaryl Compounds
1 ... 601 602 603 604 605 606 607 608 609 610 611 612 613 614 615 616 617 618 619 620 621 ... 2211